Brenig Therapeutics, founded in 2021 to design and develop breakthrough medicines for neurodegenerative disorders. It was co-founded and backed by investors, including Torrey Pines Investments, Orbimed Advisors, and Biogeneration Ventures. 

Led by a highly professional team, Brenig leverages the acceleration capabilities of Expert Systems, Inc., a leader in AI-driven drug discovery, delivering the best-in-class drug candidate to clinic from ab initio design in less then 3 years. This collaboration enhances Brenig’s pipeline potential and supports its mission to pioneer innovative therapies for neurodegenerative diseases.